| Autor: |
José Aguareles, Paula Villares Fernández, María Maravillas Carralón-González, Carles Forné Izquierdo, Eva María Martí-Ballesteros, Virginia Pradillo Fernández, Gabriel Sotres-Fernandez, Teresa García-Delangue, Rocío García de Viedma LaPetra, María Dolores Sánchez-Manzano, Carolina Gutiérrez, Marta García-Coca, Daniel Carnevali-Ruiz, Ruth Barrena-Puertas, José Manuel Luque-Pinilla, Raquel Lloris, Xavier Erik Luepke-Estefan, José Antonio López-Martín, José María Jimeno, Pablo Guisado-Vasco |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
International Journal of Infectious Diseases, Vol 135, Iss , Pp 12-17 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1201-9712 |
| DOI: |
10.1016/j.ijid.2023.07.011 |
| Popis: |
Objectives: To evaluate the compassionate use of plitidepsin as an antiviral treatment in hospitalized immunocompromised adult patients with moderate-to-severe COVID-19. Design: Retrospective observational study of data —collected from January 01, 2021 to April 30, 2022— from 35 immunocompromised adult patients with COVID-19 non-eligible for other available antiviral treatments. Main outcome measures were time to respiratory recovery (SpFi ≥ 315); COVID-19-related 30-day-cumulative mortality after first plitidepsin infusion; and time to undetectable levels of viral RNA. Results: Thirty-three patients receiving a full course of plitidepsin (2.5 mg [n = 29] or 1.5 mg [n = 4]) were included. Most (69.7%) had a malignant hematologic disease and 27.3% had solid tumors. A total of 111 infusions were administered with lack of relevant safety events. Median time from plitidepsin initiation to SpFi ≥315 was 8 days (95% confidence interval [CI], 7-19). Median time to first negative reverse transcription-polymerase chain reaction for SARS-CoV-2 (cycle threshold >36) was 17 days (95% CI 13-25). Mortality rate was 16.3% (95% CI 3-37.3). Conclusion: These data support plitidepsin as a well-tolerated treatment that might have potential clinical and antiviral efficacy in COVID-19 immunocompromised patients. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
